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Dopamine modulates the functional organization of the orbitofrontal cortex
Kahnt, Thorsten; Tobler, Philippe N
Abstract: Neuromodulators such as dopamine can alter the intrinsic firing properties of neurons, and may
thereby change the configuration of larger functional circuits. The primate orbitofrontal cortex (OFC)
receives dopaminergic input from midbrain nuclei, but the role of dopamine in the OFC is still unclear.
Here we tested the idea that dopaminergic activity changes the pattern of connectivity between the OFC
and the rest of the brain, and thereby reconfigures functional networks in the OFC. To this end, we
combined double-blind, placebo-controlled pharmacology (D2 receptor [D2R] antagonist amisulpride) in
humans with resting-state functional magnetic resonance imaging (fMRI) and clustering methods. In the
placebo group, we replicated previously observed parcellations of the OFC into two and six subregions
based on connectivity patterns with the rest of the brain. Most importantly, while the 2-fold clustering
did not differ significantly between groups, blocking D2R receptors significantly changed the composition
of the 6-fold parcellation, suggesting a dopamine-dependent reconfiguration of functional OFC subregions.
Moreover, multivariate decoding analyses revealed that amisulpride changed the whole-brain connectiv-
ity patterns of individual OFC-subregions. In particular, D2R blockade shifted the balance of OFC
connectivity from associative areas in the temporal and parietal lobe toward functional connectivity with
the frontal cortex. In summary, our results suggest that dopamine alters the composition of functional
OFC circuits, possibly indicating a broader role for neuromodulators in the dynamic reconfiguration of
functional brain networks. SIGNIFICANCE STATEMENT: A key role of any neuromodulator may be
the reconfiguration of functional brain circuits. Here we test this idea with regard to dopamine and the
organization of functional networks in the OFC. We show that blockade of dopamine D2-receptors has
profound effects on the functional connectivity patterns of the OFC, yielding in altered connectivity-based
subdivisions of this region. Our results suggest that dopamine changes the connectional configuration
of the OFC, possibly leading to transitions between different operating modes that favor either sensory
input or recurrent processing in the prefrontal cortex. More generally, our findings support a broader role
for neuromodulators in the dynamic reconfiguration of functional brain networks and may have clinical
implications for understanding the actions of antipsychotics.
DOI: https://doi.org/10.1523/JNEUROSCI.2827-16.2016
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WKH WLPHVHULHV FRUUHODWLRQ ZLWK HYHU\ RWKHU YR[HO LQ WKH UHVWRIEUDLQ PDVN ZDV FRPSXWHG  7KH UHVXOWLQJϭϰϳ








'LIIHUHQW YR[HO VL]HV ZHUH XVHG WR PDLQWDLQ KLJK VSDWLDO UHVROXWLRQ LQ WKH 2)& ZKLOH DFFRPPRGDWLQJϭϱϰ
FRPSXWDWLRQDODQGPHPRU\OLPLWDWLRQV7KLVUHVXOWHGLQD'FRUUHODWLRQPDWUL[1 2)&E\0 ϭϱϱ
UHVWRIEUDLQ YR[HOVZKHUH HDFK URZ UHIOHFWV WKH E\0ZKROHEUDLQ FRQQHFWLYLW\ SDWWHUQ RI RQH2)&YR[HOϭϱϲ
,PSRUWDQWO\ EHFDXVH YR[HOV ZHUH LQ01, VSDFH HDFK YR[HO KDV DSSUR[LPDWHO\ WKH VDPH DQDWRPLFDO SRVLWLRQϭϱϳ
DFURVV VXEMHFWV DOORZLQJ DYHUDJLQJ RI FRQQHFWLYLW\PDWULFHV  $FFRUGLQJO\ LQGLYLGXDO PDWULFHV ZHUH DYHUDJHGϭϱϴ
DFURVVVXEMHFWVDIWHUWUDQVIRUPLQJWKHFRUUHODWLRQFRHIILFLHQWVLQWR)LVKHU¶V=VFRUHV7KHUHVXOWLQJ1E\0PDWUL[ϭϱϵ
ZDVEDFNWUDQVIRUPHG LQWR3HDUVRQ FRUUHODWLRQ FRHIILFLHQWV DQGFRQWDLQHG WKHDYHUDJHZKROHEUDLQ FRQQHFWLYLW\ϭϲϬ
SDWWHUQVRIDOO2)&YR[HOVϭϲϭ
7KH SDUFHOODWLRQ ZDV SHUIRUPHG XVLQJ WKH KPHDQV FOXVWHULQJ DOJRULWKP kmeans DV LPSOHPHQWHG LQϭϲϮ
0$7/$%XVLQJWKHµFRUUHODWLRQ¶RSWLRQLHRQHPLQXVWKHFRUUHODWLRQEHWZHHQWKHFRQQHFWLYLW\SDWWHUQVRI2)&ϭϲϯ
YR[HOVDVGLVWDQFHPHDVXUH %DVHGRQRXUSUHYLRXV VWXG\ .DKQWHW DOZHFRPSXWHGFOXVWHU VROXWLRQVϭϲϰ
ZLWKK    . DQGK    . FOXVWHUV  )RU HDFKK WKH SDUFHOODWLRQZDV SHUIRUPHG  WLPHV RQFH IRU WKHϭϲϱ
SODFHERJURXSRQFH IRU WKHDPLVXOSULGHJURXSDQGRQFH IRUDOO VXEMHFWV WRJHWKHU XVLQJDZHLJKWHGDYHUDJH WRϭϲϲ
DFFRXQW IRU WKH XQHTXDO JURXS VL]HV  7KH SDUFHOODWLRQ ZDV SHUIRUPHG IRU DOO YR[HOV LQ ERWK KHPLVSKHUHVϭϲϳ
VLPXOWDQHRXVO\ 7KDW LV IRU HDFKK WKH FRQQHFWLYLW\SDWWHUQV IURPDOO2)&YR[HOVZHUH VXEMHFWHG WR D VLQJOHϭϲϴ
SDUFHOODWLRQLUUHVSHFWLYHRIWKHDQDWRPLFDOSRVLWLRQLHKHPLVSKHUHRIDJLYHQYR[HO)RUHDFKKZHXVHGWKHϭϲϵ
EHVWVROXWLRQIURPUHSHWLWLRQVZLWKGLIIHUHQWLQLWLDOFHQWURLGVϭϳϬ
1RWH WKDW WKH QRPLQDO ODEHOV DVVLJQHG WR WKH FOXVWHUV DUH DUELWUDU\ DQG GR QRWPHDVXUH DQ\WKLQJ EH\RQGϭϳϭ
FOXVWHU identity  7R DLG YLVXDO LQVSHFWLRQ DQG YLVXDO FRPSDULVRQ EHWZHHQ JURXSZLVH SDUFHOODWLRQV DQG DVϭϳϮ
UHTXLUHPHQWIRUFRPSDULQJWKHQXPEHURIYR[HOVSHUFOXVWHUEHWZHHQJURXSV WKHJURXSZLVHSDUFHOODWLRQVZHUHϭϳϯ













ܸܫሺܥǡ ܥԢሻ ൌ ܪሺܥሻ ൅ ܪሺܥԢሻ െ ʹܫሺܥǡ ܥԢሻ
ZKHUHܪሺܥሻ DQGܪሺܥԢሻ DUH WKHHQWURSLHVRIFOXVWHU VROXWLRQVC DQGC’ UHVSHFWLYHO\DQGܫሺܥǡ ܥԢሻ LV WKHPXWXDOϭϴϱ
LQIRUPDWLRQEHWZHHQCDQGC’ܪሺܥሻDQGܫሺܥǡ ܥԢሻDUHFRPSXWHGDFFRUGLQJWRϭϴϲ

























ZKHUHnk LVWKHQXPEHURIYR[HOVLQFOXVWHUkDQGnLVWKHWRWDOQXPEHURI2)&YR[HOV/RZYDOXHV RI VILQGLFDWHϭϵϬ
KLJKVLPLODULW\EHWZHHQWKHWZRFOXVWHUVROXWLRQVZKHUHDVKLJKVIYDOXHVLQGLFDWHODUJHGLIIHUHQFHVϭϵϭ
)RU VWDWLVWLFDO LQIHUHQFHZHHPSOR\HGDSHUPXWDWLRQ WHVWXVLQJ WKHSDUFHOODWLRQVREWDLQHG IURPn ϭϵϮ
UDQGRP JURXS DVVLJQPHQWV  :H FRPSDUHG WKH VI RI WKH WZR HPSLULFDO JURXSZLVH SDUFHOODWLRQV ZLWK WKHϭϵϯ
GLVWULEXWLRQRIVI’sRISDLUVRISDUFHOODWLRQVREWDLQHGIURPUDQGRPO\DVVLJQHGJURXSV)RUHDFKSHUPXWDWLRQZHϭϵϰ























RQO\ LQFOXGHGYR[HOV WKDWDUHSUHVHQW LQERWKKHPLVSKHUHVDQGGLVFDUGHGDOOYR[HOV WKDWDUHSUHVHQWRQRQHVLGHϮϬϳ
RQO\  'LIIHUHQFHV LQ KHPLVSKHULF V\PPHWU\ ZHUH FRPSDUHG EHWZHHQ JURXSV DQG VWDWLVWLFDO LQIHUHQFH ZDVϮϬϴ
SHUIRUPHGXVLQJDSHUPXWDWLRQWHVWZLWKn UDQGRPJURXSDVVLJQPHQWVVHHBetween-group comparison of ϮϬϵ
parcellationsϮϭϬ
 Ϯϭϭ
Connectivity-based decoding of drug condition ϮϭϮ
,QRUGHUWRWHVWZKHWKHU'5EORFNDGHDOWHUHGWKHIXQFWLRQDOFRQQHFWLYLW\SURILOHRI2)&VXEUHJLRQVZHXVHGDϮϭϯ
EHWZHHQVXEMHFW PXOWLYDULDWH GHFRGLQJ DSSURDFK  :H DLPHG WR GHFRGH WKH GUXJ FRQGLWLRQ DPLVXOSULGH YVϮϭϰ




3HDUVRQFRUUHODWLRQEHWZHHQ WKH WLPH VHULHV LQ HDFK2)&VXEUHJLRQ DYHUDJHGDFURVVYR[HOV DQGHYHU\RWKHUϮϭϵ
YR[HO LQ WKH UHVWRIEUDLQ PDVN UHVXOWLQJ LQ WZR DQG VL[ E\0 FRQQHFWLYLW\ SDWWHUQV IRU . DQG .ϮϮϬ
UHVSHFWLYHO\)RUHDFKkLQKWKHVXEMHFWZLVHE\0FRQQHFWLYLW\SDWWHUQVZHUHPHDQQRUPDOL]HGDFURVVYR[HOVϮϮϭ
UHVXOWLQJ LQ ]HURPHDQ YHFWRUV DQG XVHG DV IHDWXUH YHFWRUV LQ D VXSSRUW YHFWRU PDFKLQH 690 FODVVLILHUϮϮϮ











6SHFLILFDOO\ZH UHSHDWHG WKH LGHQWLFDO VWHS FURVVYDOLGDWLRQ SURFHGXUH GHVFULEHG DERYHZLWK WKH H[FHSWLRQϮϯϮ
WKDWDIWHUUDQGRPO\GUDZLQJVXEMHFWVDQGDVVLJQLQJWZRVXEMHFWVDVWHVWGDWDZHUDQGRPO\VKXIIOHGWKHJURXSϮϯϯ
ODEHOVLQWKHWUDLQLQJDQGWKHWHVWGDWD7KLVZDVUHSHDWHGWLPHVWRJHQHUDWHDGLVWULEXWLRQRIDFFXUDFLHV7KHϮϯϰ
HPSLULFDOO\REVHUYHGGHFRGLQJDFFXUDF\ ZDVFRQVLGHUHGVLJQLILFDQW LI ODUJHUGHFRGLQJDFFXUDFLHVZHUHIRXQG LQϮϯϱ
OHVVWKDQRIWKHUDQGRPSHUPXWDWLRQVpϮϯϲ
Ϯϯϳ





ܣ ൌ ܵ௫ܹ ௚ܵିଵ
:KHUHW LV WKHZHLJKW YHFWRU RI WKH690GHFRGHU DQG6[ DQG6J DUH WKH FRYDULDQFHPDWULFHV RI WKH WUDLQLQJϮϰϯ
IHDWXUHVDQGODEHOVUHVSHFWLYHO\Ϯϰϰ

















































































































































































































































































































































































































































































































K6: pla. > amisulp.
K6: pla. > amisulp.
K2: pla. > amisulp.
K2: pla. > amisulp.
A B
C D
# voxel clust. 1
-1000 0 1000
0
# voxel clust. 2
-1000 0 1000
0

























# voxel clust. 3
-500 0 500
0
# voxel clust. 2
-500 0 500
0
# voxel clust. 6
-500 0 500
# voxel clust. 1
-500 0 500


















OFC subregion OFC subregion
















































K2 - cluster 1 K2 - cluster 2A B
placebo > amisulprideamisulpride > placebo Z = 4.72Z = 3.72 Z = 4.72Z = 3.72
K6 - cluster 1
K6 - cluster 3
A B K6 - cluster 2
K6 - cluster 6C D
placebo > amisulprideamisulpride > placebo Z = 4.72Z = 3.72 Z = 4.72Z = 3.72
 ϭ
7DEOH'RSDPLQHGHSHQGHQWFRQQHFWLYLW\RIVXEUHJLRQVLQWKH.SDUFHOODWLRQ
 6LGH $QDWRPLFDOODEHO 01,[\] 1YR[HO =VFRUH
Cluster 1 - Amisulpride > Placebo     
 / DP\JGDODKLSSRFDPSXV     
 / VXSHULRUIURQWDOJ\UXV     
 5 VXSHULRUIURQWDOJ\UXV     
 / DQWHULRUFLQJXODWHFRUWH[     
 / VXSHULRUIURQWDOJ\UXV     
 / PLGGOHIURQWDOJ\UXV     
 / LQVXOD     
 5 LQVXOD     
 / PLGGOHWHPSRUDOJ\UXV     
 5 PLGGOHWHPSRUDOJ\UXV     
 / PLGGOHWHPSRUDOJ\UXV     
 / LQIHULRUWHPSRUDOFRUWH[     
 5 LQIHULRUWHPSRUDOFRUWH[     
 / SUHFXQHXV     
 / LQIHULRUSDULHWDOOREH     
Cluster 1 - Placebo > Amisulpride     
 5 PLGGOHIURQWDOJ\UXV     
 5 VXSHULRUIURQWDOJ\UXV     
 5 SUHFHQWUDOJ\UXV     
 / SRVWFHQWUDOJ\UXV     
 / PLGGOHWHPSRUDOJ\UXV     
 / IXVLIRUPJ\UXV     
 5 IXVLIRUPJ\UXV     
 / SUHFXQHXV     
 5 SUHFXQHXV    
 5 VXSHULRUSDULHWDOOREH     
 / LQIHULRUSDULHWDOOREH     
 5 LQIHULRUSDULHWDOOREH     
 5 RFFLSLWDOFRUWH[     
Cluster 3 - Amisulpride > Placebo     
 / PHGLDOIURQWDOJ\UXV     
 / PLGGOHIURQWDOJ\UXV     
 / LQVXOD     
Cluster 2 - Placebo > Amisulpride     
 5 PLGEUDLQ     
 / )XVLIRUPJ\UXV     
 / SUHFXQHXV     





 6LGH 5HJLRQ 01,[\] 1YR[HO =VFRUH
Cluster 1 - Amisulpride > Placebo     
 / VXSHULRUIURQWDOJ\UXV     
 / VXSHULRUIURQWDOJ\UXV     
 / VXSHULRUIURQWDOJ\UXV     
 5 VXSHULRUIURQWDOJ\UXV     
 / PLGGOHIURQWDOJ\UXV     
 / DQWHULRUFLQJXODWHFRUWH[     
 / LQVXOD     
 5 LQVXOD     
 / PLGGOHWHPSRUDOJ\UXV     
 5 PLGGOHWHPSRUDOJ\UXV     
 / LQIHULRUWHPSRUDOJ\UXV     
 5 LQIHULRUWHPSRUDOJ\UXV     
 / LQIHULRUSDULHWDOOREH     
Cluster 1 - Placebo > Amisulpride     
 5 VXSHULRUIURQWDOJ\UXV     
 5 PLGGOHIURQWDOJ\UXV     
 / SRVWFHQWUDOJ\UXV     
 5 SRVWFHQWUDOJ\UXV     
 / LQIHULRUWHPSRUDOJ\UXV     
 5 LQIHULRUWHPSRUDOJ\UXV     
 / LQIHULRUWHPSRUDOJ\UXV     
 5 VXSHULRUSDULHWDOJ\UXV     
 5 SUHFXQHXV     
 / SUHFXQHXV     
 / LQIHULRUSDULHWDOOREH     
 5 LQIHULRUSDULHWDOOREH     
 5 RFFLSLWDOFRUWH[     
Cluster 2 - Amisulpride > Placebo     
 / DP\JGDODKLSSRFDPSXV     
 5 PLGGOHIURQWDOJ\UXV     
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